论文部分内容阅读
目的评价CYP3A5基因多态性与肾移植受者西罗莫司的血药浓度与每千克体质量剂量比值(C0/D)的相关性。方法检索相关数据库,收集CYP3A5基因多态性与肾移植受者西罗莫司C0/D的相关性研究,对纳入文献提取有效数据后应用Rev Man5.3软件进行Meta分析,得出合并后的OR值及95%CI。结果共纳入5篇文献,合计466例患者。Meta分析结果表明,CYP3A5*3/*3基因型的西罗莫司C0/D显著高于CYP3A5*1/*1和CYP3A5*1/*3基因型(P<0.000 01)。结论 CYP3A5基因多态性与肾移植患者术后西罗莫司用药安全性和有效性密切相关,应根据CYP3A5基因型做到个性化给药。
Objective To evaluate the association between CYP3A5 gene polymorphism and the plasma concentration of sirolimus in renal transplant recipients and the ratio of C0 / D per kilogram of body mass. Methods The related databases were searched and the correlation between CYP3A5 gene polymorphisms and C0 / D of sirolimus in renal transplant recipients was collected. Meta-analysis was performed using Rev Man5.3 software after the valid data were included in the literature. The results showed that the combined OR value and 95% CI. Results A total of 5 articles were included, a total of 466 patients. Meta analysis showed that the C0 / D of sirolimus of CYP3A5 * 3 / * 3 genotype was significantly higher than that of CYP3A5 * 1 / * 1 and CYP3A5 * 1 / * 3 genotypes (P <0.000 01). Conclusion The CYP3A5 gene polymorphism is closely related to the safety and efficacy of sirolimus in patients after renal transplantation, and should be personalized according to CYP3A5 genotype.